An Abbott (NYSE:ABT) official has shared a significant reimbursement win for its Esprit BTK drug-eluting scaffold system. On LinkedIn, SVP and President of Abbott Vascular, Julie Tyler, posted that the Centers for Medicare & Medicaid Services (CMS) approved transitional pass-through (TPT) payment status for Esprit BTK. TPT, a three-year program, ensures that Medicare beneficiaries can […]
Implants
The biggest diabetes tech news out of ATTD 2026
Diabetes technology innovators gathered in Barcelona last week for the 19th annual Advanced Technologies and Treatments for Diabetes Conference (ATTD 2026). At ATTD 2026, a range of companies shared the latest updates, including product launches, new clinical data, enhancements to existing offerings and more. Topics included automated insulin delivery, continuous glucose monitors (CGMs), and breakthroughs […]
Senseonics reports sustained year-long CGM implant outcomes, insulin pump integration benefits
Senseonics (Nasdaq:SENS) announced new data from a real-world study demonstrating the sustained performance of its Eversense 365 CGM. Real-world evidence demonstrated the long-term performance and positive impact of the world’s first year-long continuous glucose monitor (CGM). The company shared findings at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Barcelona. […]
Sequel, Senseonics announce full launch of Eversense 365 CGM, twiist pump pairing
Sequel Med Tech and Senseonics (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration. Manchester, New Hampshire-based Sequel and Germantown, Maryland-based Senseonics now offer the Eversense 365 continuous glucose monitor (CGM) with the twiist automated insulin delivery (AID) system for people with type 1 diabetes in the U.S. The companies […]
Portal Diabetes earns FDA breakthrough nod for implantable insulin pump
Portal Diabetes announced today that it received FDA breakthrough device designation for its implantable insulin pump system. The Westfield, Indiana–based company can now begin a Phase 1 study to evaluate its proprietary, temperature-stable insulin. It aims to deliver a functional cure for type 1 diabetes. Portal Diabetes developed its system, called the Portal Pump, to […]
Senseonics wins CE mark for Eversense 365 year-long CGM
Senseonics (NYSE:SENS) announced today that its Eversense 365 continuous glucose monitor (CGM) system received CE mark approval. Germantown, Maryland-based Senseonics received FDA clearance for Eversense 365 in September 2024. It launched the year-long CGM implant with its global distribution partner, Ascensia Diabetes Care, the following month. It has since taken over full commercial activity for […]
Glucotrack picks up new patents for continuous blood glucose monitor
Glucotrack (Nasdaq:GCTK) announced today that it received new U.S. patents for its continuous blood glucose monitoring (CBGM) platform. The U.S. Patent and Trademark Office (USPTO) issued Patent Nos. US 12,453,494, US 12,458,257 and US 12,458,258. These patents strengthen the company’s competitive position and intellectual property protection as it advances its CBGM system toward commercialization. Glucotrack’s […]
Glaukos gets FDA nod for iDose TR re-administration
Glaukos (NYSE:GKOS) announced today that the FDA approved a new drug application (NDA) labeling supplement for its iDose TR system. iDose TR (travoprost intracameral implant) offers the reduction of intraocular pressure (IOP). It treats patients with ocular hypertension (OHT) or open-angle glaucoma (OAG). The first-of-its-kind, long-duration, intracameral procedural pharmaceutical therapy. It continuously delivers 24/7 therapeutic […]
Ripple Therapeutics, Bausch + Lomb partner on drug delivery implants for retinal diseases
Ripple Therapeutics announced today that it entered into a deal with a Bausch + Lomb affiliate related to drug delivery technology. Toronto-based Ripple develops a patented technology platform based on drugs chemically engineered into controlled-release pharmaceuticals without the use of polymers. The proprietary prodrugs undergo surface erosion to give zero-order release kinetics. They are highly […]
Glucotrack now expects spring 2026 FDA IDE submission for implantable CGM
Glucotrack (Nasdaq:GCTK) today announced a slight delay in its plans to submit its long-term glucose monitor to the FDA for IDE. The company said in August that it expected a fourth-quarter investigational device exemption (IDE) submission for the long-term implantable continuous blood glucose monitor (CBGM). However, it says today that it anticipates a submission in […]
